23andMe (ME) Stock Forecast, Price Target & Predictions
ME Stock Forecast
23andMe stock forecast is as follows: an average price target of $3.71 (represents a 31.10% upside from ME’s last price of $2.83) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ME Price Target
The average price target for 23andMe (ME) is $3.71 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $0.42. This represents a potential 31.10% upside from ME's last price of $2.83.
ME Analyst Ratings
According to 2 Wall Street analysts, 23andMe's rating consensus is 'Buy'. The analyst rating breakdown for ME stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
23andMe Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 16, 2024 | Daniel Grosslight | Citigroup | $0.42 | $0.34 | 23.53% | -85.16% |
| Nov 29, 2022 | - | Berenberg Bank | $7.00 | $2.76 | 153.62% | 147.35% |
The latest 23andMe stock forecast, released on Sep 16, 2024 by Daniel Grosslight from Citigroup, set a price target of $0.42, which represents a 23.53% increase from the stock price at the time of the forecast ($0.34), and a -85.16% decrease from ME last price ($2.83).
23andMe Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $0.42 | $0.42 |
| Last Closing Price | $2.83 | $2.83 | $2.83 |
| Upside/Downside | -100.00% | -85.16% | -85.16% |
In the current month, the average price target of 23andMe stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to 23andMe's last price of $2.83. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | Citigroup | Neutral | Neutral | Hold |
| May 28, 2024 | Citigroup | Neutral | Neutral | Hold |
| May 24, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Apr 15, 2024 | Citigroup | Neutral | Neutral | Hold |
23andMe's last stock rating was published by Citigroup on Sep 16, 2024. The company gave ME a "Neutral" rating, the same as its previous rate.
23andMe Financial Forecast
23andMe Revenue Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $44.75M | $50.00M | $60.86M | $92.38M | $66.94M | $75.66M | $64.51M | $100.56M | $56.89M | $55.20M |
| Avg Forecast | $48.76M | $41.10M | $36.41M | $53.80M | $55.82M | $54.03M | $56.80M | $56.90M | $88.40M | $65.90M | $63.54M | $61.60M | $102.79M | $54.30M | $55.71M |
| High Forecast | $48.76M | $41.10M | $36.41M | $53.80M | $55.82M | $54.03M | $56.80M | $56.90M | $88.40M | $65.90M | $63.54M | $61.60M | $102.79M | $54.30M | $55.71M |
| Low Forecast | $48.76M | $41.10M | $36.41M | $53.80M | $55.82M | $54.03M | $56.80M | $56.90M | $88.40M | $65.90M | $63.54M | $61.60M | $102.79M | $54.30M | $55.71M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | 0.83% | 0.88% | 1.07% | 1.04% | 1.02% | 1.19% | 1.05% | 0.98% | 1.05% | 0.99% |
23andMe's average Quarter revenue forecast for Mar 24 based on 1 analysts is $55.82M, with a low forecast of $55.82M, and a high forecast of $55.82M. ME's average Quarter revenue forecast represents a 24.75% increase compared to the company's last Quarter revenue of $44.75M (Dec 23).
23andMe EBITDA Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | $126.70M | $-65.71M | $-109.26M | $-60.91M | $-97.10M | $-58.63M | $-80.18M | $-69.45M | $-85.33M | $-11.65M |
| Avg Forecast | $-40.14M | $-33.84M | $-29.98M | $-44.29M | $-45.96M | $-44.48M | $-46.76M | $-46.85M | $-72.78M | $-54.25M | $-51.76M | $-50.18M | $-62.84M | $-44.24M | $-45.39M |
| High Forecast | $-40.14M | $-33.84M | $-29.98M | $-44.29M | $-45.96M | $-44.48M | $-46.76M | $-46.85M | $-72.78M | $-54.25M | $-51.76M | $-50.18M | $-50.27M | $-44.24M | $-45.39M |
| Low Forecast | $-40.14M | $-33.84M | $-29.98M | $-44.29M | $-45.96M | $-44.48M | $-46.76M | $-46.85M | $-72.78M | $-54.25M | $-51.76M | $-50.18M | $-75.40M | $-44.24M | $-45.39M |
| Surprise % | - | - | - | - | - | -2.85% | 1.41% | 2.33% | 0.84% | 1.79% | 1.13% | 1.60% | 1.11% | 1.93% | 0.26% |
1 analysts predict ME's average Quarter EBITDA for Mar 24 to be $-45.96M, with a high of $-45.96M and a low of $-45.96M. This is -136.27% lower than 23andMe's previous annual EBITDA (Dec 23) of $126.70M.
23andMe Net Income Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | $-277.98M | $-75.27M | $-104.62M | $-64.10M | $-91.96M | $-66.06M | $-89.53M | $-69.54M | $-89.40M | $13.40M |
| Avg Forecast | $-62.07M | $-81.31M | $-80.45M | $-112.17M | $-84.73M | $-71.39M | $-71.72M | $-76.37M | $-81.04M | $-97.14M | $-1.69B | $-1.59B | $-69.54M | $-1.56B | $-1.26B |
| High Forecast | $-62.07M | $-81.31M | $-80.45M | $-112.17M | $-84.73M | $-71.39M | $-56.35M | $-76.37M | $-81.04M | $-97.14M | $-1.69B | $-1.59B | $-55.64M | $-1.56B | $-1.26B |
| Low Forecast | $-62.07M | $-81.31M | $-80.45M | $-112.17M | $-84.73M | $-71.39M | $-87.08M | $-76.37M | $-81.04M | $-97.14M | $-1.69B | $-1.59B | $-83.45M | $-1.56B | $-1.26B |
| Surprise % | - | - | - | - | - | 3.89% | 1.05% | 1.37% | 0.79% | 0.95% | 0.04% | 0.06% | 1.00% | 0.06% | -0.01% |
23andMe's average Quarter net income forecast for Dec 21 is $-1.56B, with a range of $-1.56B to $-1.56B. ME's average Quarter net income forecast represents a -11751.50% decrease compared to the company's last Quarter net income of $13.40M (Sep 21).
23andMe SG&A Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | $57.18M | $40.98M | $73.40M | $48.54M | $70.58M | $50.45M | $63.08M | $66.19M | $71.43M | $29.85M |
| Avg Forecast | $35.02M | $29.52M | $26.15M | $38.64M | $40.10M | $38.81M | $40.80M | $40.87M | $63.50M | $47.33M | $46.20M | $44.79M | $66.19M | $39.48M | $40.51M |
| High Forecast | $35.02M | $29.52M | $26.15M | $38.64M | $40.10M | $38.81M | $40.80M | $40.87M | $63.50M | $47.33M | $46.20M | $44.79M | $79.42M | $39.48M | $40.51M |
| Low Forecast | $35.02M | $29.52M | $26.15M | $38.64M | $40.10M | $38.81M | $40.80M | $40.87M | $63.50M | $47.33M | $46.20M | $44.79M | $52.95M | $39.48M | $40.51M |
| Surprise % | - | - | - | - | - | 1.47% | 1.00% | 1.80% | 0.76% | 1.49% | 1.09% | 1.41% | 1.00% | 1.81% | 0.74% |
23andMe's average Quarter SG&A projection for Mar 24 is $40.10M, based on 1 Wall Street analysts, with a range of $40.10M to $40.10M. The forecast indicates a -29.88% fall compared to ME last annual SG&A of $57.18M (Dec 23).
23andMe EPS Forecast
| Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | $-0.58 | $-0.16 | $-0.23 | $-0.14 | $-0.20 | $-0.15 | $-0.20 | $-0.16 | $-0.21 | $0.03 |
| Avg Forecast | $-2.43 | $-3.19 | $-3.15 | $-4.40 | $-3.32 | $-2.80 | $-2.81 | $-2.99 | $-3.18 | $-3.81 | $-3.41 | $-3.21 | $-2.54 | $-3.15 | $-2.53 |
| High Forecast | $-2.43 | $-3.19 | $-3.15 | $-4.40 | $-3.32 | $-2.80 | $-2.21 | $-2.99 | $-3.18 | $-3.81 | $-3.41 | $-3.21 | $-2.54 | $-3.15 | $-2.53 |
| Low Forecast | $-2.43 | $-3.19 | $-3.15 | $-4.40 | $-3.32 | $-2.80 | $-3.41 | $-2.99 | $-3.18 | $-3.81 | $-3.41 | $-3.21 | $-2.54 | $-3.15 | $-2.53 |
| Surprise % | - | - | - | - | - | 0.21% | 0.06% | 0.08% | 0.04% | 0.05% | 0.04% | 0.06% | 0.06% | 0.07% | -0.01% |
According to 1 Wall Street analysts, 23andMe's projected average Quarter EPS for Dec 21 is $-3.15, with a low estimate of $-3.15 and a high estimate of $-3.15. This represents a -9669.09% decrease compared to ME previous annual EPS of $0.03 (Sep 21).
23andMe Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| DMTK | DermTech | $0.09 | $15.00 | 16566.67% | Buy |
| GH | Guardant Health | $28.96 | $57.27 | 97.76% | Buy |
| ILMN | Illumina | $130.74 | $202.44 | 54.84% | Buy |
| DHR | Danaher | $230.06 | $305.47 | 32.78% | Buy |
| ME | 23andMe | $2.83 | $3.71 | 31.10% | Buy |
| TMO | Thermo Fisher Scientific | $501.29 | $642.48 | 28.17% | Buy |
| A | Agilent | $126.92 | $152.64 | 20.26% | Buy |
| IDXX | IDEXX Laboratories | $419.83 | $479.75 | 14.27% | Buy |
| TWST | Twist Bioscience | $41.43 | $42.40 | 2.34% | Buy |
| WAT | Waters | $355.47 | $356.80 | 0.37% | Buy |
| HTGM | HTG Molecular Diagnostics | $0.48 | $0.17 | -64.58% | Buy |